EVAX Fundamental Analysis - EVAXION A/S

Name: EVAXION A/S (EVAX) Stock
Brand: EVAXION A/S
Rating: 6.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to EVAX. EVAX was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EVAX has reported negative net income.

In the past year EVAX has reported a negative cash flow from operations.

EVAX had negative earnings in each of the past 5 years.

In the past 5 years EVAX always reported negative operating cash flow.

1.2 Ratios

EVAX has a Return On Assets (-53.34%) which is in line with its industry peers.

With a Return On Equity value of -192.34%, EVAX is not doing good in the industry: 66.29% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-53.34%
ROE	-192.34%
ROIC	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EVAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

EVAX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for EVAX has been reduced compared to 5 years ago.

The debt/assets ratio for EVAX has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -0.23, we must say that EVAX is in the distress zone and has some risk of bankruptcy.

EVAX has a Altman-Z score of -0.23. This is comparable to the rest of the industry: EVAX outperforms 58.24% of its industry peers.

A Debt/Equity ratio of 1.73 is on the high side and indicates that EVAX has dependencies on debt financing.

EVAX has a Debt to Equity ratio of 1.73. This is in the lower half of the industry: EVAX underperforms 79.21% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.73
Debt/FCF	N/A
Altman-Z	-0.23

ROIC/WACCN/A

WACC5.52%

2.3 Liquidity

A Current Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.

EVAX has a Current ratio of 3.42. This is in the lower half of the industry: EVAX underperforms 60.49% of its industry peers.

A Quick Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.

The Quick ratio of EVAX (3.42) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.42
Quick Ratio	3.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.02%, which is quite impressive.

EVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 1042.45%.

EPS 1Y (TTM)76.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%96.67%

Revenue 1Y (TTM)1042.45%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-75.97%

3.2 Future

Based on estimates for the next years, EVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.29% on average per year.

The Revenue is expected to grow by 61.85% on average over the next years. This is a very strong growth

EPS Next Y23.5%

EPS Next 2Y19.2%

EPS Next 3Y92.2%

EPS Next 5Y15.29%

Revenue Next Year14.94%

Revenue Next 2Y0.95%

Revenue Next 3Y118.03%

Revenue Next 5Y61.85%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EVAX's earnings are expected to grow with 92.20% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.2%

EPS Next 3Y92.2%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EVAX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVAXION A/S

NASDAQ:EVAX (10/30/2025, 11:21:55 AM)

5.82

+0.07 (+1.22%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-29 2025-10-29

Earnings (Next)03-30 2026-03-30/amc

Inst Owners1.91%

Inst Owner Change-0.15%

Ins Owners0.68%

Ins Owner ChangeN/A

Market Cap36.76M

Revenue(TTM)3.18M

Net Income(TTM)-11975000

Analysts82.5

Price Target13.77 (136.6%)

Short Float %8.85%

Short Ratio0.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)60.81%

Min EPS beat(2)24.59%

Max EPS beat(2)97.03%

EPS beat(4)4

Avg EPS beat(4)54.87%

Min EPS beat(4)11.56%

Max EPS beat(4)97.03%

EPS beat(8)7

Avg EPS beat(8)54.84%

EPS beat(12)10

Avg EPS beat(12)37.39%

EPS beat(16)13

Avg EPS beat(16)31.2%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)10%

PT rev (3m)-71.05%

EPS NQ rev (1m)159.7%

EPS NQ rev (3m)158.82%

EPS NY rev (1m)25.44%

EPS NY rev (3m)3.89%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)492.66%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	11.58
P/FCF	N/A
P/OCF	N/A
P/B	5.9
P/tB	5.9
EV/EBITDA	N/A

EPS(TTM)-4.22

EYN/A

EPS(NY)-1.62

Fwd EYN/A

FCF(TTM)-1.85

FCFYN/A

OCF(TTM)-1.85

OCFYN/A

SpS0.5

BVpS0.99

TBVpS0.99

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-53.34%
ROE	-192.34%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	1.73
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.42
Quick Ratio	3.42
Altman-Z	-0.23

F-Score6

WACC5.52%

ROIC/WACCN/A

Cap/Depr(3y)21.76%

Cap/Depr(5y)127.17%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)76.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%96.67%

EPS Next Y23.5%

EPS Next 2Y19.2%

EPS Next 3Y92.2%

EPS Next 5Y15.29%

Revenue 1Y (TTM)1042.45%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-75.97%

Revenue Next Year14.94%

Revenue Next 2Y0.95%

Revenue Next 3Y118.03%

Revenue Next 5Y61.85%

EBIT growth 1Y26.91%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y50.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.7%

OCF growth 3YN/A

OCF growth 5YN/A

EVAXION A/S / EVAX FAQ

Can you provide the ChartMill fundamental rating for EVAXION A/S?

ChartMill assigns a fundamental rating of 2 / 10 to EVAX.

What is the valuation status of EVAXION A/S (EVAX) stock?

ChartMill assigns a valuation rating of 1 / 10 to EVAXION A/S (EVAX). This can be considered as Overvalued.

Can you provide the profitability details for EVAXION A/S?

EVAXION A/S (EVAX) has a profitability rating of 0 / 10.

How financially healthy is EVAXION A/S?

The financial health rating of EVAXION A/S (EVAX) is 3 / 10.

What is the earnings growth outlook for EVAXION A/S?

The Earnings per Share (EPS) of EVAXION A/S (EVAX) is expected to grow by 23.5% in the next year.

EVAXION A/S (EVAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EVAXION A/S / EVAX FAQ

Can you provide the ChartMill fundamental rating for EVAXION A/S?

What is the valuation status of EVAXION A/S (EVAX) stock?

Can you provide the profitability details for EVAXION A/S?

How financially healthy is EVAXION A/S?

What is the earnings growth outlook for EVAXION A/S?